Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 3, 1997, Pages 311-321

  Olbricht, Christoph ^b   Wanner, Christoph ^b   Eisenhauer, Thomas ^b   Kliem, Volker ^b   Doll, Rainer ^b   Boddaert, Michel ^b   O'Grady, Padraig ^b   Krekler, Michael ^b   Mangold, Bernhard ^b   Christians, Uwe ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MYOGLOBIN; NIFEDIPINE; NITRENDIPINE; PRAVASTATIN; TRIACYLGLYCEROL; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LOVASTATIN; MIDDLE AGED; PRAVASTATIN;

EID: 12644251055     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90034-5     Document Type: Article

References (36)

1. Pirsch JD, D'Alessandro AM, Sollinger HW, Knechtle SJ, Reed A, Kalayoglu M, et al. Hyperlipemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 1992;2:S238-42.
2. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84:985-92.
3. Castelao AM, Grinyo JM, Castineiras MJ, Fiol C, Gilvernet S, Seron D, et al. Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc 1995;27:2217-20.
4. Rehman MA, Al-Sulaiman MH, Mousa DH, Al-Hawas FA, Abdalla AH, Rassoul Z, et al. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine. Transplantation 1995;27:397-9.
5. Cheung AK, De Vault GA, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993;3:1884-91.
6. Yoshimura N, Oka T, Okamoto M, Ohomori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992;53:94-9.
7. Yoshimura N, Ohmori Y, Tsuji T, Oka T. Effect of pravastatin on renal transplant recipients treated with cyclosporine- 4 year follow-up. Transplant Proc 1994; 26:2632-3.
8. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin; IV: identification of cytochrome P450 3A proteins as the major enzymes responsible for oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290: 355-61.
9. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
10. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
11. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin. N Engl J Med 1988;318:47-8.
12. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25: 2732-4.
13. EEC/CPMP Working Party. Good clinical practice for trials on medical products in the European Community. III/3976/88-EN draft No 3; August 17, 1989.
14. Morris MJ, Gilbert DJ, Hsieh JYK, Matuszewski BK, Ramjit HG, Bayne WF. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biol Mass Spectrom 1993;22:1-8.
15. Christians U, Zimmer KO, Wonigeit K, Maurer G, Sewing KF. Liquid-chromatographic measurement of cyclosporin and its metabolites in blood, bile and urine. Clin Chem 1988;34:34-9.
16. Food and Drug Administration. Good laboratory practice regulations: final rule. Federal Register 1987; 52:33768-82.
17. Holt DW, Marsden JT, Johnson A. Quality assessment of cyclosporine measurements: comparison of current methods. Transplant Proc 1990;22:1234-9.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem 1972;18:499-502.
19. Thompson GR. Quantitation of blood lipids and lipoproteins. In: A handbook of hyperlipidaemia. London: Current Science; 1989. p. 43-58.
20. Farmer RH, Muniak JF, Pittman KA. Management of PK data using HP3357 mainframe IBM interfacing. Drug Info J 1987;21:141-52.
21. Heinzel G, Woloszczak R, Thomann P. TopFit 2.0: pharmacokinetic and pharmacodynamic data analysis for the PC. Stuttgart: Gustav Fischer Verlag; 1993.
22. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. Br Med J 1988;296:1454-6.
23. Kolars JC, Stetson PL, Rush BD, Ruwart MJ, Schmiedlin-Ren P, Duell EA, et al. Cyclosporin A metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? Transplantation 1992;53:596-602.
24. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocyte drug metabolism barriers to drug absorption. Adv Drug Delivery Rev 1996;20:99-112.
25. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Tkahagi H, et al. Biotransformation of pravastatin sodium; I: mechanism of enzymic transformation of epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993;192:597-602.
26. Pan HY, Funke PT, Willard DA, MC Kinstry DN. Pharmacokinetics, pharmacodynamics and safety of pravastatin sodium, a potent inhibitor of HMG-CoA reductase, in healthy volunteers. In: LaRosa C. New advances in the control of lipid metabolism: focus on pravastatin. London: Royal Society of Medicine Services; 1989. p. 9-21.
27. Quion JAV, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994;27:94-103.
28. Neuvonen PJ, Jalava MD. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
29. Combalbert J, Fabre I, Fabre G, Daleti I, Derancourt J, Cano JP, et al. Metabolism of cyclosporin A; IV: purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
30. Ziegler K, Blumrich M, Hummelsiep S. The transporter for the HMG-CoA reductase inhibitor pravastatin is not present in HEP G2 cells: evidence for the nonidentity of the carrier for pravastatin and certain transport systems for BSP. Biochim Biophys Acta 1994;1223:195-201.
31. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988;8:239-41.
32. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-5.
33. Alejandro DS, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol 1994;5:153-60.
34. Marinella MA. More on lovastatin. West J Med 1995; 162:176-7.
35. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol 1990;65:23F-6F.
36. Hsu I, Spinier SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-59.